Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Chemotherapy Based on Organoid for Colorectal Cancer
NCT05832398Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- May 2023
- Primary completion
- Jan 2025
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised trial of fluorouracil, oxaliplatin and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Progression-free survival at 1 year. Started May 2023; status: recruiting.
02
Drugs
fluorouraciloxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05832398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832398.